Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

266 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer.
Castagnoli L, Iorio E, Dugo M, Koschorke A, Faraci S, Canese R, Casalini P, Nanni P, Vernieri C, Di Nicola M, Morelli D, Tagliabue E, Pupa SM. Castagnoli L, et al. Among authors: nanni p. J Cell Physiol. 2019 Feb;234(2):1768-1779. doi: 10.1002/jcp.27049. Epub 2018 Aug 21. J Cell Physiol. 2019. PMID: 30132876 Free PMC article.
Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab.
Castagnoli L, Iezzi M, Ghedini GC, Ciravolo V, Marzano G, Lamolinara A, Zappasodi R, Gasparini P, Campiglio M, Amici A, Chiodoni C, Palladini A, Lollini PL, Triulzi T, Menard S, Nanni P, Tagliabue E, Pupa SM. Castagnoli L, et al. Among authors: nanni p. Cancer Res. 2014 Nov 1;74(21):6248-59. doi: 10.1158/0008-5472.CAN-14-0983. Epub 2014 Aug 27. Cancer Res. 2014. PMID: 25164009
Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer.
Castagnoli L, Ghedini GC, Koschorke A, Triulzi T, Dugo M, Gasparini P, Casalini P, Palladini A, Iezzi M, Lamolinara A, Lollini PL, Nanni P, Chiodoni C, Tagliabue E, Pupa SM. Castagnoli L, et al. Among authors: nanni p. Oncogene. 2017 Mar 23;36(12):1721-1732. doi: 10.1038/onc.2016.338. Epub 2016 Sep 19. Oncogene. 2017. PMID: 27641338 Free PMC article.
HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response.
Palladini A, Nicoletti G, Lamolinara A, Dall'Ora M, Balboni T, Ianzano ML, Laranga R, Landuzzi L, Giusti V, Ceccarelli C, Santini D, Taffurelli M, Di Oto E, Asioli S, Amici A, Pupa SM, De Giovanni C, Tagliabue E, Iezzi M, Nanni P, Lollini PL. Palladini A, et al. Among authors: nanni p. Oncotarget. 2017 Apr 13;8(33):54444-54458. doi: 10.18632/oncotarget.17088. eCollection 2017 Aug 15. Oncotarget. 2017. PMID: 28903354 Free PMC article.
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft.
Landuzzi L, Palladini A, Ceccarelli C, Asioli S, Nicoletti G, Giusti V, Ruzzi F, Ianzano ML, Scalambra L, Laranga R, Balboni T, Arigoni M, Olivero M, Calogero RA, De Giovanni C, Dall'Ora M, Di Oto E, Santini D, Foschini MP, Cucchi MC, Zanotti S, Taffurelli M, Nanni P, Lollini PL. Landuzzi L, et al. Among authors: nanni p. Sci Rep. 2021 Jan 15;11(1):1563. doi: 10.1038/s41598-021-81085-y. Sci Rep. 2021. PMID: 33452364 Free PMC article.
Immunological prevention of a multigene cancer syndrome.
Croci S, Nicoletti G, Landuzzi L, De Giovanni C, Astolfi A, Marini C, Di Carlo E, Musiani P, Forni G, Nanni P, Lollini PL. Croci S, et al. Among authors: nanni p. Cancer Res. 2004 Nov 15;64(22):8428-34. doi: 10.1158/0008-5472.CAN-04-2341. Cancer Res. 2004. PMID: 15548714
266 results